Obagi Medical and Aesthetic Record Announce Collaboration in the ALOHA Program to Drive Real-World Evidence for Obagi® saypha® MagIQ(TM)
MWN-AI** Summary
Obagi Medical and Aesthetic Record have announced a strategic collaboration under the ALOHA Program, aimed at generating real-world evidence for Obagi's saypha® MagIQ™ injectable. This partnership leverages Aesthetic Record's robust electronic medical records (EMR) platform, utilized by over 9,000 aesthetic clinics, to translate clinical data from FDA pivotal trials into practical applications in everyday aesthetic practices.
The ALOHA Program will provide Aesthetic Record users with hands-on experience using Obagi saypha® MagIQ™, while also evaluating comprehensive Obagi skincare protocols. According to Dr. Tiphany Hall of Aesthetic Record, the collaboration is centered around enhancing patient experience through best-in-class tools that align with Obagi's evidence-based approach to launching innovative products.
As part of the initiative, Aesthetic Record will conduct a real-world clinical program, capturing standardized data through its analytics capabilities. The findings will be presented at significant industry conferences, showcasing the impact of the new injectable and the value embedded in the Aesthetic Record ecosystem. Drew Fine, U.S. General Manager for Obagi, emphasized that this partnership signifies a commitment to a differentiated launch strategy, aiming to collect high-quality data more efficiently than traditional methods.
Developed by Croma-Pharma GmbH, the saypha® MagIQ™ injectable incorporates proprietary MACRO Core Technology, which aims to provide natural-looking results with superior performance attributes. Obagi Medical, recognized for its legacy spanning over 35 years in skincare innovation, continuously strives to empower practices and individuals to achieve healthy skin.
This collaboration not only represents a significant advancement in the aesthetics industry but also positions both companies to capitalize on growing market trends through a unified approach to skincare and injectables.
MWN-AI** Analysis
Obagi Medical's recent collaboration with Aesthetic Record for the ALOHA Program marks a pivotal strategy to leverage real-world evidence in the aesthetics market. This partnership is not just a mere alliance but a calculated move to enhance the adoption of Obagi’s innovative injectable, saypha® MagIQ™. By integrating clinical efficacy with everyday practice using Aesthetic Record’s extensive platform, which supports over 9,000 aesthetic clinics, Obagi is setting the stage for a differentiated launch that aligns with industry demands for accountability in treatment outcomes.
The ALOHA Program is positioned to generate substantial real-world data, providing a strong foundation that can translate into improved patient satisfaction and enhanced provider relationships. In an age where patients are increasingly savvy and demand transparent results, this program will equip providers with the data they need to instill confidence in their treatments.
From a market perspective, Waldencast plc, Obagi's parent company, stands to gain significantly by positioning itself as a forward-thinking leader in the aesthetics space. The focus on the injectable segment is timely, given the growing consumer demand for non-invasive skin solutions. Analysts should closely monitor initial findings that will be showcased at the upcoming Aesthetic Next conference, as this data will be critical for investor sentiment and market responsiveness.
Moreover, Obagi's commitment to continuous innovation, underpinned by robust clinical research and a keen focus on user experience through Aesthetic Record’s platform, suggests an optimistic growth trajectory. Investors may want to consider increasing exposure to Obagi Medical as the ALOHA initiative unfolds. The success of this program could solidify Obagi’s market position and unlock further avenues for growth in the booming aesthetics industry, positioning it as a compelling investment opportunity.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
NEW YORK and IRVING, Texas, Feb. 17, 2026 (GLOBE NEWSWIRE) -- Obagi Medical, a leading innovator in physician-dispensed skincare and aesthetic solutions and part of Waldencast plc (NASDAQ: WALD) (“Waldencast” or the “Company”), today announced Aesthetic Record as a key partner for the Aesthetics Leadership with Obagi’s Hyaluronic Acid (ALOHA) Program. Aesthetic Record will help generate real-world data to translate the clinical safety and efficacy demonstrated in FDA pivotal trials into everyday practice across multiple trials and evaluation programs, leveraging its seamless EMR, charting, analytics, and integrated tools used by over 9,000 aesthetic clinics.
“This partnership with Obagi aligns with our mission to enhance the patient experience by equipping practices with best-in-class tools. They're taking a thoughtful, evidence-based approach to launching this innovative injectable, and we have the technology platform and reach to capture how practices translate that information into treating patients day-to-day,” said Tiphany Hall, PhD, Chief Growth Office at Aesthetic Record. “Our users are in high-volume practices, offering a diverse portfolio of treatments, all with efficient charting, photo documentation, compliance monitoring and performance tracking. An integrated experience matters for busy practices. This is the kind of collaborative work that advances the aesthetics industry by combining cutting-edge injectables with streamlined technology and comprehensive skincare protocols to yield better patient outcomes. Obagi’s focus on real-world insights aligns with our mission to empower practices with tools that simplify operations and elevate care.”
The ALOHA Real-World Program is designed to give Aesthetic Record users hands-on experience with Obagi saypha® MagIQ™ while evaluating complete Obagi protocols. This approach aims to drive patient satisfaction and strengthen relationships between patients and their providers. The program includes a real-world clinical initiative supplemented by a structured evaluation process across multiple Aesthetic Record-supported practices and providers, with standardized data capture facilitated through the platform's powerful analytics and reporting capabilities.
Aesthetic Record will present initial findings at the upcoming Aesthetic Next conference, highlighting the benefits of the new protocols and product within the Aesthetic Record ecosystem. Results will also be presented at key industry conferences to demonstrate the real-world impact of introducing this innovative injectable across thousands of aesthetic practices powered by Aesthetic Record.
“Partnering with Aesthetic Record is a clear statement of our intent to launch this new injectable beyond the typical approaches,” said Drew Fine, U.S. General Manager, Professional Channel. “By leveraging Aesthetic Record’s advanced technology platform, we can drive launch success in a more efficient and scalable manner, capturing high-quality real-world data faster and more comprehensively than traditional methods. The ALOHA program will serve as a platform for a differentiated launch strategy and underscore Obagi Medical’s commitment to delivering innovative products across every facet of skincare and now injectable aesthetics.”
Obagi® saypha® MagIQ™, developed by Croma-Pharma GmbH, utilizes proprietary MACRO Core Technology to create a stable three-dimensional hyaluronic acid matrix. The technology is designed to deliver natural-looking results with category-leading performance, including high usable HA content upon injection, consistent gel distribution, and a predictable injection force and swelling profile¹.
For more information about ALOHA, visit https://obagi-professional.com.
About Obagi Medical
Obagi Medical is an industry-leading, advanced skincare line rooted in research and skin biology, with a legacy of 35+ years of experience. Initially known for its leadership in the treatment of hyperpigmentation with the Obagi Nu-Derm® System, Obagi Medical products are designed to address a variety of skin concerns, including premature aging, photodamage, skin discoloration, acne, and sun damage. As the fastest-growing professional skincare brand in the U.S. in 2024,² Obagi Medical empowers individuals to achieve healthy, beautiful skin. More information about Obagi Medical is available on the brand's website, https://www.obagi.com.
About Aesthetic Record
Aesthetic Record is the industry's leading Electronic Medical Records (EMR) and Practice Management platform built exclusively for medical aesthetics. Trusted by thousands of practices, from startups to enterprise groups, Aesthetic Record streamlines clinical documentation, patient engagement, operations, and financial performance within a single, integrated ecosystem. By empowering practices with end-to-end solutions, including marketing automation, e-commerce, compliance, and payment processing, Aesthetic Record helps providers simplify, scale, and succeed at the speed of aesthetics.
About Waldencast plc
Founded by Michel Brousset and Hind Sebti, Waldencast’s ambition is to build a global best-in-class beauty and wellness operating platform by developing, acquiring, accelerating, and scaling conscious, high-growth purpose-driven brands. Waldencast’s vision is fundamentally underpinned by its brand-led business model that ensures proximity to its customers, business agility, and market responsiveness, while maintaining each brand’s distinct DNA. For more information please visit: https://ir.waldencast.com.
Media Contact:
obagi@behrmancesa.com
Source: Waldencast plc
¹ Puljic A, Frank K, Cohen J, Otto K, Mayr J, Hugh-Bloch A, Kuroki-Hasenöhrl, D. A Scientific Framework for Comparing Hyaluronic Acid Filler Crosslinking Technologies. Gels. 2025; 11(7):487
² Among the Top 10 Professional Skin Care Brands in the U.S., According to Kline’s 2024 Global Professional Skin Care Series (China, Europe and the U.S.)
FAQ**
How does the partnership between Aesthetic Record and Obagi Medical, a subsidiary of Waldencast Acquisition Corp. WALD, enhance the integration of real-world data into the clinical practices of aesthetic providers?
What specific advantages does Obagi’s saypha® MagIQ™ injectable offer, compared to other products in the market, as described by executives from Waldencast Acquisition Corp. WALD?
In what ways does the ALOHA Program aim to improve patient satisfaction and treatment outcomes within the aesthetic practices utilizing the Waldencast Acquisition Corp. WALD technology platform?
How will initial findings from the ALOHA Real-World Program be presented at industry conferences, and why is this significant for Waldencast Acquisition Corp. WALD's market positioning in the aesthetics sector?
**MWN-AI FAQ is based on asking OpenAI questions about Waldencast Acquisition Corp. (NASDAQ: WALD).
NASDAQ: WALD
WALD Trading
3.9% G/L:
$1.60 Last:
8,798 Volume:
$1.56 Open:
